Atenção!


O atendimento às questões referentes ao Repositório Institucional será interrompido entre os dias 20 de dezembro de 2025 a 4 de janeiro de 2026.

Pedimos a sua compreensão e aproveitamos para desejar boas festas!

Logo do repositório

Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry

dc.contributor.authorBiasoli, Irene
dc.contributor.authorCastro, Nelson
dc.contributor.authorDelamain, Marcia
dc.contributor.authorSilveira, Talita
dc.contributor.authorFarley, James
dc.contributor.authorSimões, Belinda Pinto
dc.contributor.authorSolza, Cristiana
dc.contributor.authorPraxedes, Monica
dc.contributor.authorBaiocchi, Otávio
dc.contributor.authorGaiolla, Rafael [UNESP]
dc.contributor.authorFranceschi, Fernanda
dc.contributor.authorSola, Caroline Bonamin
dc.contributor.authorBoquimpani, Carla
dc.contributor.authorClementino, Nelma
dc.contributor.authorPerini, Guilherme
dc.contributor.authorPagnano, Kátia
dc.contributor.authorSteffenello, Giovanna
dc.contributor.authorTabacof, Jacques
dc.contributor.authorde Freitas Colli, Gilberto
dc.contributor.authorSoares, Andrea
dc.contributor.authorde Souza, Carmino
dc.contributor.authorChiattone, Carlos Sérgio
dc.contributor.authorMilito, Cristiane
dc.contributor.authorMorais, José Carlos
dc.contributor.authorSpector, Nelson
dc.contributor.institutionUniversidade Federal do Rio de Janeiro (UFRJ)
dc.contributor.institutionHospital de Cancer de Barretos
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.contributor.institutionSão Paulo Santa Casa Medical School
dc.contributor.institutionLiga Norte Rio Grandense Contra o Cancer
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade do Estado do Rio de Janeiro (UERJ)
dc.contributor.institutionUniversidade Federal Fluminense (UFF)
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionFundação Amaral Carvalho
dc.contributor.institutionUniversidade Federal do Paraná (UFPR)
dc.contributor.institutionHEMORIO
dc.contributor.institutionUniversidade Federal de Minas Gerais (UFMG)
dc.contributor.institutionHospital Israelita Albert Einstein-SP
dc.contributor.institutionUniversidade Federal de Santa Catarina (UFSC)
dc.contributor.institutionESHO-Centro Paulistano de Oncologia
dc.date.accessioned2018-12-11T16:47:54Z
dc.date.available2018-12-11T16:47:54Z
dc.date.issued2018-02-01
dc.description.abstractData about Hodgkin lymphoma (HL) in developing countries are scarce and suggest the existence of substantial disparities in healthcare and outcomes in large areas of the world. In 2009, a prospective registry of HL was implemented in Brazil. Web-based data were contributed by 20 institutions across the country participating in the Brazilian Prospective Hodgkin's Lymphoma Registry. The aim of this study was to present the clinical features and outcomes of newly diagnosed patients with HL aged 13 to 90 years. Multivariate Cox regression models were used to estimate progression-free (PFS) and overall survival (OS) by clinical factors. A total of 674 patients with classical HL were analysed, with a median follow-up of 37 months. Median age was 30 years (13-90). The median time from the onset of symptoms to diagnosis was 6 months (0-60). Only 6% of patients had early favourable disease, while 65% had advanced disease. Stage IVB was present in 26% and a high-risk International Prognostic Score in 38%. Doxorubicin, bleomycin, vinblastine, and dacarbazine was used in 93%. The median dose of radiotherapy was 36 Gy for localized disease and 32 Gy for advanced disease. The 3 year PFS in early favourable, early unfavourable, and advanced disease were 95%, 88%, and 66%, respectively. High-risk International Prognostic Score, advanced disease, and age greater than or equal to 60 were independently associated with poorer PFS and OS; performance status greater than or equal to 2 was also associated with a poorer OS. Poor-risk patients predominated. Radiation doses for localized disease appear higher than current recommendations. Outcomes appear inferior in developing countries than in developed countries. Delayed diagnosis is probably a major factor underlying these findings. Scattered reports from developing nations suggest that many aspects of standard care in developed countries remain unmet needs for populations living in developing countries. The present report contributes to this body of data, with a proper description of what is currently achieved in urban areas in Brazil.en
dc.description.affiliationSchool of Medicine Universidade Federal do Rio de Janeiro
dc.description.affiliationHospital de Cancer de Barretos
dc.description.affiliationHematology and Hemotherapy Center University of Campinas
dc.description.affiliationSão Paulo Santa Casa Medical School
dc.description.affiliationLiga Norte Rio Grandense Contra o Cancer
dc.description.affiliationUSP-Ribeirão Preto
dc.description.affiliationUniversidade do Estado do Rio de Janeiro
dc.description.affiliationUniversidade Federal Fluminense
dc.description.affiliationUNIFESP
dc.description.affiliationUNESP
dc.description.affiliationFundação Amaral Carvalho
dc.description.affiliationUniversidade Federal do Paraná
dc.description.affiliationHEMORIO
dc.description.affiliationUniversidade Federal de Minas Gerais
dc.description.affiliationHospital Israelita Albert Einstein-SP
dc.description.affiliationUniversidade Federal de Santa Catarina
dc.description.affiliationESHO-Centro Paulistano de Oncologia
dc.description.affiliationUnespUNESP
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipIdCNPq: 440567/2014-9
dc.format.extent189-195
dc.identifierhttp://dx.doi.org/10.1002/hon.2450
dc.identifier.citationHematological Oncology, v. 36, n. 1, p. 189-195, 2018.
dc.identifier.doi10.1002/hon.2450
dc.identifier.issn1099-1069
dc.identifier.issn0278-0232
dc.identifier.scopus2-s2.0-85021211586
dc.identifier.urihttp://hdl.handle.net/11449/169856
dc.language.isoeng
dc.relation.ispartofHematological Oncology
dc.relation.ispartofsjr0,605
dc.relation.ispartofsjr0,605
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectBrazil
dc.subjectHodgkin lymphoma
dc.subjectoutcomes
dc.subjectregistry
dc.titleTreatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registryen
dc.typeArtigo
dspace.entity.typePublication
unesp.author.orcid0000-0001-7265-7691[1]

Arquivos

Coleções